Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

2021; Elsevier BV; Volume: 4; Issue: 2 Linguagem: Inglês

10.1016/s2665-9913(21)00327-1

ISSN

2665-9913

Autores

Nádia Emi Aikawa, Léonard de Vinci Kanda Kupa, Sandra Gofinet Pasoto, Ana Cristina de Medeiros Ribeiro, Emily Figueiredo Neves Yuki, Carla Gonçalves Schahin Saad, Tatiana do Nascimento Pedrosa, Ricardo Fuller, Samuel Katsuyuki Shinjo, Percival D. Sampaio‐Barros, Danieli Andrade, Rosa Maria Rodrigues Pereira, Luciana Parente Costa Seguro, Juliana Miranda Lucena Valim, Filipe Waridel, Ana Marli C Sartori, Alberto J. S. Duarte, Leila Antonângelo, Éster Cerdeira Sabino, Paulo Rossi Menezes, Esper G. Kallás, Clóvis A. Silva, Eloísa Bonfá,

Tópico(s)

Dermatological and COVID-19 studies

Resumo

We aimed to examine the immunogenicity pattern induced by the inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Life Sciences, Beijing, China) in SARS-CoV-2 seropositive patients with autoimmune rheumatic diseases compared with seropositive controls, seronegative patients with autoimmune rheumatic diseases, and seronegative controls.

Referência(s)